Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361947662> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4361947662 abstract "<div>AbstractPurpose:<p>Glioblastomas (GBMs), neoplasms derived from glia and neuroglial progenitor cells, are the most common and lethal malignant primary brain tumors diagnosed in adults, with a median survival of 14 months. GBM tumorigenicity is often driven by genetic aberrations in receptor tyrosine kinases, such as amplification and mutation of EGFR.</p>Experimental Design:<p>Using a <i>Drosophila</i> glioma model and human patient–derived GBM stem cells and xenograft models, we genetically and pharmacologically tested whether the YAP and TAZ transcription coactivators, effectors of the Hippo pathway that promote gene expression via TEA domain (TEAD) cofactors, are key drivers of GBM tumorigenicity downstream of oncogenic EGFR signaling.</p>Results:<p>YAP and TAZ are highly expressed in EGFR-amplified/mutant human GBMs, and their knockdown in EGFR-amplified/mutant GBM cells inhibited proliferation and elicited apoptosis. Our results indicate that YAP/TAZ-TEAD directly regulates transcription of <i>SOX2</i>, <i>C-MYC</i>, and <i>EGFR</i> itself to create a feedforward loop to drive survival and proliferation of human GBM cells. Moreover, the benzoporphyrin derivative verteporfin, a disruptor of YAP/TAZ-TEAD–mediated transcription, preferentially induced apoptosis of cultured patient-derived EGFR-amplified/mutant GBM cells, suppressed expression of YAP/TAZ transcriptional targets, including EGFR, and conferred significant survival benefit in an orthotopic xenograft GBM model. Our efforts led us to design and initiate a phase 0 clinical trial of Visudyne, an FDA-approved liposomal formulation of verteporfin, where we used intraoperative fluorescence to observe verteporfin uptake into tumor cells in GBM tumors in human patients.</p>Conclusions:<p>Together, our data suggest that verteporfin is a promising therapeutic agent for EGFR-amplified and -mutant GBM.</p></div>" @default.
- W4361947662 created "2023-04-05" @default.
- W4361947662 creator A5014453774 @default.
- W4361947662 creator A5019951975 @default.
- W4361947662 creator A5021453253 @default.
- W4361947662 creator A5026892408 @default.
- W4361947662 creator A5037315999 @default.
- W4361947662 creator A5040717966 @default.
- W4361947662 creator A5073097799 @default.
- W4361947662 creator A5088305334 @default.
- W4361947662 date "2023-03-31" @default.
- W4361947662 modified "2023-10-16" @default.
- W4361947662 title "Data from YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma" @default.
- W4361947662 doi "https://doi.org/10.1158/1078-0432.c.6529980" @default.
- W4361947662 hasPublicationYear "2023" @default.
- W4361947662 type Work @default.
- W4361947662 citedByCount "0" @default.
- W4361947662 crossrefType "posted-content" @default.
- W4361947662 hasAuthorship W4361947662A5014453774 @default.
- W4361947662 hasAuthorship W4361947662A5019951975 @default.
- W4361947662 hasAuthorship W4361947662A5021453253 @default.
- W4361947662 hasAuthorship W4361947662A5026892408 @default.
- W4361947662 hasAuthorship W4361947662A5037315999 @default.
- W4361947662 hasAuthorship W4361947662A5040717966 @default.
- W4361947662 hasAuthorship W4361947662A5073097799 @default.
- W4361947662 hasAuthorship W4361947662A5088305334 @default.
- W4361947662 hasBestOaLocation W43619476622 @default.
- W4361947662 hasConcept C104317684 @default.
- W4361947662 hasConcept C143065580 @default.
- W4361947662 hasConcept C172512520 @default.
- W4361947662 hasConcept C173396325 @default.
- W4361947662 hasConcept C190283241 @default.
- W4361947662 hasConcept C2777933648 @default.
- W4361947662 hasConcept C502942594 @default.
- W4361947662 hasConcept C54355233 @default.
- W4361947662 hasConcept C62478195 @default.
- W4361947662 hasConcept C86339819 @default.
- W4361947662 hasConcept C86803240 @default.
- W4361947662 hasConcept C95444343 @default.
- W4361947662 hasConceptScore W4361947662C104317684 @default.
- W4361947662 hasConceptScore W4361947662C143065580 @default.
- W4361947662 hasConceptScore W4361947662C172512520 @default.
- W4361947662 hasConceptScore W4361947662C173396325 @default.
- W4361947662 hasConceptScore W4361947662C190283241 @default.
- W4361947662 hasConceptScore W4361947662C2777933648 @default.
- W4361947662 hasConceptScore W4361947662C502942594 @default.
- W4361947662 hasConceptScore W4361947662C54355233 @default.
- W4361947662 hasConceptScore W4361947662C62478195 @default.
- W4361947662 hasConceptScore W4361947662C86339819 @default.
- W4361947662 hasConceptScore W4361947662C86803240 @default.
- W4361947662 hasConceptScore W4361947662C95444343 @default.
- W4361947662 hasLocation W43619476621 @default.
- W4361947662 hasLocation W43619476622 @default.
- W4361947662 hasOpenAccess W4361947662 @default.
- W4361947662 hasPrimaryLocation W43619476621 @default.
- W4361947662 hasRelatedWork W1939426260 @default.
- W4361947662 hasRelatedWork W2095426342 @default.
- W4361947662 hasRelatedWork W2102289484 @default.
- W4361947662 hasRelatedWork W2344074251 @default.
- W4361947662 hasRelatedWork W2783081400 @default.
- W4361947662 hasRelatedWork W3047599533 @default.
- W4361947662 hasRelatedWork W3092500847 @default.
- W4361947662 hasRelatedWork W3156319284 @default.
- W4361947662 hasRelatedWork W4324139288 @default.
- W4361947662 hasRelatedWork W4384488757 @default.
- W4361947662 isParatext "false" @default.
- W4361947662 isRetracted "false" @default.
- W4361947662 workType "article" @default.